ABSTRACT

Objective: To examine associations between ischemic stroke, vascular risk factors, and MRI markers of brain aging.

Methods: Eighty-one patients (mean age 67.5 ± 13.1 years, 31 left-sided, 61 men) with confirmed first-ever (n = 66) or recurrent (n = 15) ischemic stroke underwent 3T MRI scanning within 6 weeks of symptom onset (mean 26 ± 9 days). Age-matched controls (n = 40) completed identical testing. Multivariate regression analyses examined associations between group membership and MRI markers of brain aging (cortical thickness, total brain volume, white matter hyperintensity [WMH] volume, hippocampal volume), normalized against intracranial volume, and the effects of vascular risk factors on these relationships.

Results: First-ever stroke was associated with smaller hippocampal volume (p = 0.025) and greater WMH volume (p = 0.004) relative to controls. Recurrent stroke was in turn associated with smaller hippocampal volume relative to both first-ever stroke (p = 0.017) and controls (p = 0.001). These associations remained significant after adjustment for age, sex, education, and, in stroke patients, infarct volume. Total brain volume was not significantly smaller in first-ever stroke patients than in controls (p = 0.056), but the association became significant after further adjustment for atrial fibrillation (p = 0.036). Cortical thickness and brain volumes did not differ as a function of stroke type, infarct volume, or etiology.

Conclusions: Brain structure is likely to be compromised before ischemic stroke by vascular risk factors. Smaller hippocampal and total brain volumes and increased WMH load represent proxies for underlying vascular brain injury.

GLOSSARY

AF = atrial fibrillation; BMI = body mass index; CANVAS = Cognition and Neocortical Volume After Stroke; CI = confidence interval; ICV = intracranial volume; SE = standard error; TOAST = Trial of Org 10172 in Acute Stroke Treatment; T2DM = type II diabetes mellitus; WMH = white matter hyperintensity.

Ischemic stroke is associated with an increased risk of dementia, and the risk is even higher in recurrent stroke. The mechanisms underlying poststroke dementia are unclear. Macrovascular and microvascular disease, including cumulative microinfarct burden, may drive progressive cell loss and white matter degeneration. Cerebral infarcts are associated with secondary neurodegeneration in functionally and structurally connected brain regions, including areas distant to the primary lesion site. Vascular risk factors can also contribute to cerebral hypoperfusion and structural brain aging, with the hippocampi particularly vulnerable to vascular burden. Hippocampal atrophy is a cardinal feature of Alzheimer disease and is associated with dementia after stroke. The quantification of brain volume early after ischemic stroke allows the investigation of the effects on brain structure of both the stroke lesion and preexisting vascular risk factors. In the

From the Florey Institute of Neuroscience and Mental Health (E.W., T.C., Q.L., L.B., M.V., H.R.P., G.J., G.A.D., A.B.), University of Melbourne; Austin Health (G.J., A.B.), Heidelberg, and Eastern Clinical Research Unit (A.B.), Monash University, Box Hill Hospital, Melbourne, Victoria, Australia.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Cognition and Neocortical Volume After Stroke (CANVAS) study, we examine structural MRI markers of brain aging (hippocampal volume, total brain volume, cortical thickness, white matter hyperintensity [WMH]) volume in prospectively recruited ischemic stroke patients scanned within 6 weeks after stroke (25.5 ± 9.2 [7–42] days). We compare their results with results from age-matched controls who underwent identical scanning.

Given the deleterious effects of vascular burden and stroke on brain structure, we hypothesized that recurrent stroke patients would have smaller total and regional brain volumes than first-ever stroke patients and controls and that brain volumes would in turn be smaller in first-ever stroke patients than controls.

**METHODS**

Standard protocol approvals, registrations, and patient consents. The study was approved by human research ethics committees of Austin Health, Eastern Health, and Melbourne Health. Informed consent was obtained from all participants.

**Participants.** The CANVAS study design and methodology have been described in detail previously. Briefly, patients with ischemic stroke, confirmed clinically and radiologically, were recruited within 6 weeks of their event from the acute stroke units at 3 hospitals in Melbourne, Australia (Austin Health, Box Hill Hospital, and Royal Melbourne Hospital). Patients with first-ever or recurrent ischemic stroke in any vascular territory and of any etiology according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) and Oxfordshire classifications were included. Stroke patients were deemed ineligible if they received a diagnosis of TIA or primary hemorrhagic stroke, but ischemic stroke patients with secondary hemorrhagic transformation were included. Healthy control participants were selected from a larger database of volunteers who had previously undertaken MRI research at the Florey Institute of Neuroscience and Mental Health on the basis that they had no history of stroke or TIA and were of a comparable age, sex, and education to stroke patients. All participants had no history of dementia, neurodegenerative disorders, major psychiatric illnesses, or substance abuse problems.

Eighty-three stroke participants were scanned within 6 weeks of their ischemic stroke (25.5 ± 9.2 [7–42] days after stroke). One participant was withdrawn from the study after extensive clinical investigations did not confirm ischemic stroke. MRI data for one stroke participant was excluded because of excessive movement. Eighty-one stroke patients had usable MRI data.

### Table 1: Demographic, clinical, and vascular risk characteristics of the sample

<table>
<thead>
<tr>
<th>Demographic and clinical factors</th>
<th>RS</th>
<th>FE</th>
<th>HC</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic and clinical factors</strong></td>
<td></td>
<td></td>
<td></td>
<td>RS-FE</td>
</tr>
<tr>
<td>Age, y, median (IQR)</td>
<td>15</td>
<td>75 (66–80)</td>
<td>66</td>
<td>68 (60.75–74)</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
<td>15</td>
<td>11 (73.3)</td>
<td>66</td>
<td>50 (75.8)</td>
</tr>
<tr>
<td>Education, mean ± SD, y</td>
<td>15</td>
<td>11.87 ± 3.3</td>
<td>66</td>
<td>12.90 ± 3.88</td>
</tr>
<tr>
<td>MoCA score, median (IQR)</td>
<td>14</td>
<td>22 (19–25.3)</td>
<td>64</td>
<td>24 (22–26.8)</td>
</tr>
<tr>
<td>IQCODE score, median (IQR)</td>
<td>11</td>
<td>3.3 (3–3.43)</td>
<td>41</td>
<td>3 (3–3.13)</td>
</tr>
<tr>
<td>APOE ε4, n (%)</td>
<td>9</td>
<td>2 (22.2)</td>
<td>50</td>
<td>10 (20)</td>
</tr>
<tr>
<td>Married, n (%)</td>
<td>15</td>
<td>7 (46.7)</td>
<td>66</td>
<td>45 (68.2)</td>
</tr>
<tr>
<td>Depression, n (%)</td>
<td>15</td>
<td>3 (20)</td>
<td>66</td>
<td>7 (10.6)</td>
</tr>
<tr>
<td>Stroke FH, n (%)</td>
<td>13</td>
<td>6 (46.2)</td>
<td>64</td>
<td>18 (27.3)</td>
</tr>
<tr>
<td>Dementia FH, n (%)</td>
<td>13</td>
<td>1 (7.7)</td>
<td>63</td>
<td>10 (15.9)</td>
</tr>
<tr>
<td>Vascular risk factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>15</td>
<td>11 (73.3)</td>
<td>66</td>
<td>35 (53)</td>
</tr>
<tr>
<td>High cholesterol, n (%)</td>
<td>15</td>
<td>9 (60)</td>
<td>66</td>
<td>27 (40.9)</td>
</tr>
<tr>
<td>T2DM, n (%)</td>
<td>15</td>
<td>6 (40)</td>
<td>66</td>
<td>14 (21.2)</td>
</tr>
<tr>
<td>AF, n (%)</td>
<td>15</td>
<td>6 (40)</td>
<td>66</td>
<td>16 (24.2)</td>
</tr>
<tr>
<td>Smoking, pack-years, median (IQR)</td>
<td>14</td>
<td>4 (0–1.3)</td>
<td>65</td>
<td>1 (0–2.5)</td>
</tr>
<tr>
<td>BMI ≥25 kg/m², n (%)</td>
<td>14</td>
<td>11 (73.3)</td>
<td>66</td>
<td>53 (80.3)</td>
</tr>
</tbody>
</table>

Abbreviations: AF = atrial fibrillation; BMI = body mass index; FE = first-ever stroke; FH = family history; HC = healthy controls; IQCODE = Informant Questionnaire on Cognitive Decline in the Elderly; IQR = interquartile range; MoCA = Montreal Cognitive Assessment; RS = recurrent stroke; T2DM = type II diabetes mellitus.

*Mann-Whitney U test.

Fisher exact test.

Independent-samples t test. All tests were 2-tailed.
including 66 patients with first-ever stroke and 15 patients with recurrent stroke. No patient had an old or acute stroke involving the hippocampus. Forty healthy controls were included.

**Demographic, clinical, and vascular risk variables.** We obtained information on age, years of education, handedness, marital status, stroke, and dementia family history via interview. The Montreal Cognitive Assessment was used as a measure of cognition and administered on the day of the MRI scan. We obtained an estimate of premorbid cognitive functioning with the Informant Questionnaire on Cognitive Decline in the Elderly (table 1). We defined vascular risk factors as those modifiable and non-modifiable factors that are associated with an increased risk of cerebrovascular disease, stroke, and dementia. Depression, hypertension, type II diabetes mellitus (T2DM), hypercholesterolemia, and atrial fibrillation (AF) were defined via a physician’s diagnosis (reported by the participant) or via the use of medications for these conditions at the time of stroke or inclusion in the study (control participants). Smoking pack-years was defined as the number of cigarettes smoked per day multiplied by the number of years the participant smoked. Body mass index (BMI) was calculated from weight and height measurements obtained on the day of the assessment and divided into low (<25 kg/m²) and high (>25 kg/m²) groups.

Medical records were used to collect stroke information, including stroke side, thrombolysis treatment at the time of stroke, previous clinical stroke, and NIH Stroke Scale scores. Modified Rankin Scale (MRS) scores were obtained at the baseline assessment. An experienced stroke neurologist (A.B.) made the stroke diagnosis. Vascular risk factors were assessed for all participants (correlation coefficients <0.05). Hippocampal, WMH, and stroke infarct volumes were divided by the ICV to create a proportion. Hippocampal, WMH, and stroke infarct volumes were log-transformed after normalization against ICV because their distributions remained positively skewed. Corrected values were used in all regression analyses.

Robust regressions were used to examine associations between group membership and MRI variables. Three independent models were used. Comparisons between first-ever stroke patients and controls and between recurrent stroke patients and controls included age, sex, and education as covariates. Covariates in the recurrent and first-ever stroke comparisons included age, sex, education, and, to account for stroke size, normalized stroke infarct volume. Covariates were chosen a priori because they are known to affect brain volume. Vascular risk factors were added independently to these basic models to examine their effects on associations between group membership and MRI variables. Unstandardized regression (B) coefficients, standard errors, p values, and 95% confidence intervals (CIs) were reported for all regression analyses. Levels of α were set at 0.05 (2-tailed). For all analyses, missing data were classified as missing at random and ignored.

**RESULTS** Eighty-one stroke patients (mean age 67.5 ± 13.1 years, 31 left-sided, 61 mm) and 40 control participants were included. Demographic, clinical, and vascular risk characteristics are presented in table 1. Stroke admission characteristics for the stroke groups are presented in table e-1. Raw values for cortical thickness, total brain volume, hippocampal volume, and WMH volume are presented in the figure. In the stroke group, there were no differences in regional brain volumes between the ipsilesional and contralesional hemispheres (table e-2). Thus, all data were averaged across hemispheres. Normalized cortical thickness and brain volumes did not differ according to stroke etiology or type (p > 0.05 for all analyses of variance; data not shown).
Demographic, clinical, and vascular risk data. Relative to healthy controls, first-ever and recurrent stroke patients performed worse on the Montreal Cognitive Assessment and were less educated, less likely to report a family history of dementia, and more likely to have AF (table 1). In addition, recurrent stroke patients were more likely than controls to have T2DM. Informant Questionnaire on Cognitive Decline in the Elderly scores were similar in all groups. Recurrent and first-ever stroke patients were comparable with respect to demographic and vascular risk factors (table 1). There was no significant difference in age between these 2 groups. Stroke admission characteristics were also similar between groups, but left-sided strokes were more common in the recurrent stroke group (table e-1).

First-ever stroke patients vs healthy controls. After adjustment for age, sex, and education, first-ever stroke was significantly associated with smaller log–hippocampal volume and larger log–WMH volume but not with lower cortical thickness (table 2). The association between first-ever stroke and smaller total brain volume failed to reach statistical significance (table 2). First-ever stroke remained significantly associated with smaller log–hippocampal volume and larger log–WMH volume after the addition of each vascular risk factor to their respective models (tables e-3 and e-4).

Associations between first-ever stroke and cortical thickness remained nonsignificant with the addition of vascular risk factors; however, first-ever stroke became significantly associated with smaller total brain volume with the addition of AF to the model (table e-4).

No vascular risk factors were independently associated with log–hippocampal volume, total brain volume, or log–WMH volume (table e-4); however, a BMI >25 kg/m² was associated with smaller cortical thickness regardless of group membership.

Recurrent vs first-ever stroke patients. Recurrent stroke was significantly associated with smaller log–
hippocampal volume but not with lower cortical thickness, smaller total brain volume, or lower log-transformed WMH volume after adjustments for age, sex, education, and log–stroke infarct volume (table 2).

Recurrent stroke remained significantly associated with smaller log–hippocampal volume after the addition of each vascular risk factor (table e-4). Associations between recurrent stroke and cortical thickness, total brain volume, and log–WMH volume remained nonsignificant (table e-4). No vascular risk factors were independently associated with any MRI variable (table e-4). Log–stroke infarct volume was not independently associated with any MRI variable in the basic models (data not shown).

**Recurrent stroke patients vs healthy controls.** Recurrent stroke was significantly associated with smaller log–hippocampal volume after adjustments for age, sex, and education but not with cortical thickness, total brain volume, or log-transformed WMH volume (table 2).

The addition of vascular risk factors did not affect the results: recurrent stroke remained significantly associated with smaller log–hippocampal volume, and associations with total brain volume, cortical thickness, and log–WMH volume remained nonsignificant (table e-4).

No vascular risk factors were independently associated with log–hippocampal or total brain, volumes; however, T2DM was significantly associated with greater cortical thickness, AF was significantly associated with smaller log–WMH volume, and a BMI >25 kg/m² was significantly associated with greater log–WMH volume (table e-4).

**Associations of cortical thickness and brain volumes in stroke patients.** Robust univariate regressions were conducted to determine whether cortical thickness and brain volumes were associated with stroke admission characteristics and APOE ε4 status (table 3). Smaller hippocampal and total brain volumes were associated with greater disability (Rankin Scale score) at the time of the assessment; however, after adjustment for age, sex, education, and log–stroke infarct volume, associations with hippocampal (B = −0.01, SE = 0.01, p = 0.27, 95% CI = −0.04 to 0.01) and total brain (B = −0.001, SE = 0.001, p = 0.94, 95% CI = −0.02 to 0.02) volumes were no longer significant. Larger log–WMH volume was associated with smaller total brain volume (table 3). This association remained significant in the fully adjusted model (B = −0.02, SE = 0.01, p = 0.045, 95% CI = −0.03 to 3.6 × 10⁻⁴). No other associations were significant.

**DISCUSSION** In the first 6 weeks after stroke, we found smaller hippocampal and larger WMH volumes in first-ever stroke patients compared to
healthy, age-matched controls. Hippocampal volumes were smaller in recurrent stroke patients than in first-ever stroke patients and controls. Associations were significant after adjustments for demographic variables, vascular risk, and, in stroke patients, infarct volume. Total brain volume was significantly smaller in first-ever stroke patients relative to controls after adjustment for AF. Collectively, these results suggest that brain structure is compromised in first-ever stroke patients before their stroke, possibly by cumulative vascular disease. They also suggest that recurrent stroke may lead to accelerated hippocampal volume losses that are in addition to changes associated with exposure to vascular risk factors.

Our finding of further hippocampal volume loss in recurrent stroke patients may represent a "dose-dependent" response to incident infarction. It is consistent with human and animal studies that have reported progressive hippocampal volume loss after ischemic stroke in extrahippocampal regions and suggests that stroke may be associated with remote damage to the hippocampus. Moreover, it suggests that our recurrent stroke patients are at risk of cognitive decline and dementia.

### Table 3 Univariate robust regression analyses examining associations between clinical and stroke admission characteristics and MRI markers of brain aging

<table>
<thead>
<tr>
<th></th>
<th>B coefficient</th>
<th>SE</th>
<th>P Value</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Log-hippocampal volume</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left-sided stroke (1)</td>
<td>-0.006</td>
<td>0.01</td>
<td>0.56</td>
<td>-0.03 to 0.02</td>
</tr>
<tr>
<td>tPA (1)</td>
<td>0.005</td>
<td>0.01</td>
<td>0.73</td>
<td>0.02 to 0.03</td>
</tr>
<tr>
<td>Cortical stroke (1)</td>
<td>-0.008</td>
<td>0.01</td>
<td>0.52</td>
<td>-0.03 to 0.02</td>
</tr>
<tr>
<td>Log-WMH volume/ICV</td>
<td>-0.01</td>
<td>0.01</td>
<td>0.23</td>
<td>-0.02 to 0.006</td>
</tr>
<tr>
<td>Admission NIHSS</td>
<td>0.002</td>
<td>0.002</td>
<td>0.25</td>
<td>-0.001 to 0.005</td>
</tr>
<tr>
<td>Moderate/severe Rankin (1)</td>
<td>-0.02</td>
<td>0.01</td>
<td>0.04</td>
<td>-0.04 to -9.1 × 10⁻⁴</td>
</tr>
<tr>
<td>APOE +4 positive (1)</td>
<td>2.3 × 10⁻⁴</td>
<td>0.02</td>
<td>0.99</td>
<td>-0.03 to 0.03</td>
</tr>
<tr>
<td><strong>Total brain volume</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left-sided stroke (1)</td>
<td>-0.01</td>
<td>0.01</td>
<td>0.26</td>
<td>-0.04 to 0.01</td>
</tr>
<tr>
<td>tPA (1)</td>
<td>0.01</td>
<td>0.02</td>
<td>0.50</td>
<td>-0.02 to 0.04</td>
</tr>
<tr>
<td>Cortical stroke (1)</td>
<td>-0.006</td>
<td>0.01</td>
<td>0.59</td>
<td>-0.03 to 0.02</td>
</tr>
<tr>
<td>Log-WMH volume/ICV</td>
<td>-0.04</td>
<td>0.01</td>
<td>&lt;0.001</td>
<td>-0.05 to -0.02</td>
</tr>
<tr>
<td>Admission NIHSS</td>
<td>-0.001</td>
<td>0.002</td>
<td>0.51</td>
<td>-0.005 to 0.003</td>
</tr>
<tr>
<td>Moderate/severe Rankin (1)</td>
<td>-0.03</td>
<td>0.01</td>
<td>0.008</td>
<td>-0.05 to -0.008</td>
</tr>
<tr>
<td>APOE +4 positive (1)</td>
<td>0.02</td>
<td>0.02</td>
<td>0.28</td>
<td>-0.01 to 0.05</td>
</tr>
<tr>
<td><strong>Cortical thickness</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left-sided stroke (1)</td>
<td>-2.1 × 10⁻⁷</td>
<td>2.2 × 10⁻⁷</td>
<td>0.33</td>
<td>-6.4 × 10⁻⁷ to 2.2 × 10⁻⁷</td>
</tr>
<tr>
<td>tPA (1)</td>
<td>1.4 × 10⁻⁷</td>
<td>1.4 × 10⁻⁷</td>
<td>0.34</td>
<td>-1.5 × 10⁻⁷ to 4.2 × 10⁻⁷</td>
</tr>
<tr>
<td>Cortical stroke (1)</td>
<td>1.6 × 10⁻⁸</td>
<td>1.3 × 10⁻⁸</td>
<td>0.90</td>
<td>-2.4 × 10⁻⁷ to 2.7 × 10⁻⁷</td>
</tr>
<tr>
<td>Log-WMH volume/ICV</td>
<td>-1.3 × 10⁻⁷</td>
<td>1.2 × 10⁻⁷</td>
<td>0.25</td>
<td>-3.7 × 10⁻⁷ to 9.7 × 10⁻⁷</td>
</tr>
<tr>
<td>Admission NIHSS</td>
<td>1.2 × 10⁻⁸</td>
<td>1.8 × 10⁻⁸</td>
<td>0.51</td>
<td>-2.5 × 10⁻⁸ to 4.9 × 10⁻⁸</td>
</tr>
<tr>
<td>Moderate/severe Rankin (1)</td>
<td>-1.2 × 10⁻⁸</td>
<td>1.2 × 10⁻⁸</td>
<td>0.92</td>
<td>-2.4 × 10⁻⁷ to 2.2 × 10⁻⁷</td>
</tr>
<tr>
<td>APOE +4 positive (1)</td>
<td>2.4 × 10⁻⁷</td>
<td>2.7 × 10⁻⁷</td>
<td>0.38</td>
<td>-3 × 10⁻⁷ to 7.7 × 10⁻⁷</td>
</tr>
<tr>
<td><strong>Log-WMH volume</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left-sided stroke (1)</td>
<td>0.15</td>
<td>0.17</td>
<td>0.38</td>
<td>-0.20 to 0.50</td>
</tr>
<tr>
<td>tPA (1)</td>
<td>-0.27</td>
<td>0.22</td>
<td>0.23</td>
<td>-0.72 to 0.18</td>
</tr>
<tr>
<td>Cortical stroke (1)</td>
<td>-0.03</td>
<td>0.21</td>
<td>0.91</td>
<td>-0.45 to 0.40</td>
</tr>
<tr>
<td>Admission NIHSS</td>
<td>0.01</td>
<td>0.03</td>
<td>0.67</td>
<td>-0.05 to 0.08</td>
</tr>
<tr>
<td>Moderate/severe Rankin (1)</td>
<td>0.13</td>
<td>0.19</td>
<td>0.50</td>
<td>-0.25 to 0.51</td>
</tr>
<tr>
<td>APOE +4 positive (1)</td>
<td>-0.13</td>
<td>0.24</td>
<td>0.59</td>
<td>-0.60 to 0.35</td>
</tr>
</tbody>
</table>

Abbreviations: CI = confidence interval; ICV = intracranial volume; NIHSS = NIH Stroke Scale; tPA = tissue plasminogen activator; WMH = white matter hyperintensity.
It is possible that stroke triggered rapid hippocampal volume loss in our first-ever ischemic stroke patients, given the vulnerability of this structure to reductions in cerebral blood flow. In support of this notion, estimates of premorbid cognition were comparable between groups, but first-ever stroke patients performed worse than controls on a cognitive screening tool after stroke. However, it is unlikely that differences in hippocampal volume reported here between first-ever stroke patients and controls can be accounted for by poststroke change. We previously reported nonsignificant hippocampal volume loss in the first 3 months after stroke, comparing a 3-month scan with hyperacute scanning at 2 hours. In the animal literature, hippocampal neurodegeneration has been reported between 12 hours and 150 days after middle cerebral artery occlusion, but this is typically greater on the ipsilesional side. In the current study, hippocampal and brain volume losses were extensive and bilateral. Hippocampal volumes were also unrelated to infarct size and were not smaller in patients with posterior circulation strokes.

It is far more likely that smaller hippocampal volumes in our first-ever ischemic stroke patients represent the cumulative effect of vascular burden. In prior studies, patients have been scanned at different time points after stroke, producing conflicting results and making the effects of stroke and vascular risk factors on brain volumes difficult to separate. Our results suggest that brain volume loss and increased WMH burden are proxies for underlying vascular brain injury.

The association between first-ever stroke and smaller total brain volume was significant only after adjustment for AF. This result is unsurprising given that exposure to vascular risk factors in mid and late life is known to affect brain structure, with AF particularly detrimental to hippocampal and whole-brain volumes and white matter. The observed association between AF and reduced WMH load in the recurrent stroke and healthy control comparisons was unexpected, but we must note that this result is based on 7 participants with AF (6 recurrent stroke patients, 1 control). We confirmed an association between higher BMI and reduced cortical thickness and between higher BMI and greater WMH burden. The observed association of T2DM and greater cortical thickness may reflect a sample size or methodological issue: we examined mean cortical thickness across hemispheres, whereas prior studies have often reported region-specific cortical thinning in T2DM (e.g., right hemisphere, left anterior cingulate, temporal/parietal lobe).

The strengths of the current study include the well-characterized stroke sample, the short interval between stroke and MRI scan, and the inclusion of a healthy, age-matched control group. Moreover, all participants were scanned on the same 3T MRI machine, and a single trained investigator completed all manual hippocampal and WMH tracings. The limitations of the study include the small stroke sample size, which meant that we could not examine MRI markers of brain aging in a more homogeneous sample. It also might have influenced the size of the B coefficients and CIs observed in some of our analyses. In addition, most participants in the stroke group experienced relatively minor strokes (i.e., NIH Stroke Scale scores were between 0 and 7 at admission), meaning the sample is representative of the mild to moderate stroke population only. Finally, the results must be interpreted with caution because the control sample size was small, and although we controlled for demographic factors (e.g., age, sex, and education) in all regression analyses, controls were better educated than stroke patients.

We found smaller brain volumes and increased WMH load in first-ever ischemic stroke patients. Recurrent stroke was associated with greater hippocampal volume loss. Our findings indicate that markers of brain aging are evident shortly after first stroke, with recurrent stroke having additive effects on the hippocampus.

AUTHOR CONTRIBUTIONS

Dr. Emilio Werden: writing of manuscript; data extraction, analysis, and interpretation; statistical analysis; preparation of figure and tables.
Dr. Toby Cumming: study design and conceptualization; data interpretation; critical revision of manuscript.
Qi Li and Laura Bird: data extraction; critical revision of manuscript.
Dr. Michele Veldman: critical revision of manuscript.
Dr. Heath Pardoe: study design and conceptualization; critical revision of manuscript.
Dr. Graeme Jackson and Geoffrey Donnan: study design and conceptualization.
Dr. Amy Brodtmann: study design and conceptualization; data interpretation; critical revision of manuscript.

ACKNOWLEDGMENT

The authors thank the Victorian Life Sciences Computation Initiative at the University of Melbourne; Dr. Fiona Permezel, who kindly assisted with the hippocampal maskings; the MRI radiographers at Melbourne Brain Centre; and all our participants who generously contributed their time to the study.

STUDY FUNDING

This work was supported by the National Health and Medical Research Council project grant (APP1020526), Brain Foundation, Wicking Trust, Collie Trust, and Sidney and Fiona Myer Family Foundation. The Florey Institute of Neuroscience and Mental Health acknowledges the support received from the Victorian Government via the Operational Infrastructure Support Scheme.

DISCLOSURE

E. Werden reports no disclosures relevant to the manuscript.
T. Cumming is on the editorial board of *BMC Neurology*. Q. Li, L. Bird, M. Veldman, H. Pardoe, and G. Jackson report no disclosures relevant to the manuscript. G. Donnan is on the editorial board of *International Journal of Stroke*. A. Brodtmann is on the editorial boards of *Neurology* and *International Journal of Stroke*. Go to Neurology.org for full disclosures.

Received November 15, 2016. Accepted in final form March 16, 2017.
REFERENCES


This Week’s Neurology® Podcast

Antiepileptic drug therapy in patients with autoimmune epilepsy (see the July 2017 issue of Neurology® Neuroimmunology & Neuroinflammation)

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 11, 2017, issue of Neurology. In the first segment, Dr. Lara Marcuse talks with Dr. Anteneh Feyissa about his paper on antiepileptic drug therapy in patients with autoimmune epilepsy published in Neurology: Neuroimmunology & Neuroinflammation. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Jeffrey A. Cohen on new immunotherapies in neurology.

Disclosures can be found at Neurology.org.

At Neurology.org, click on “RSS” in the Neurology Podcast box to listen to the most recent podcast and subscribe to the RSS feed.

No CME will be offered this week: Interviews based on articles from Neurology® Clinical Practice, Neurology® Genetics, and Neurology: Neuroimmunology & Neuroinflammation are excluded from the CME program.

Visit the Neurology® Resident & Fellow Website

Click on Residents & Fellows tab at Neurology.org.

Now offering:

- Neurology® Resident & Fellow Editorial team information
- “Search by subcategory” option
- E-pearl of the Week
- RSS Feeds
- Direct links to Continuum®, Career Planning, and AAN Resident & Fellow pages
- Recently published Resident & Fellow articles
- Podcast descriptions

Find Neurology® Residents & Fellows Section on Facebook: http://tinyurl.com/o8ahsys
Follow Neurology® on Twitter: http://twitter.com/GreenJournal
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Werden, E; Cumming, T; Li, Q; Bird, L; Veldsman, M; Pardoe, HR; Jackson, G; Donnan, GA; Brodtmann, A

Title:
Structural MRI markers of brain aging early after ischemic stroke

Date:
2017-07-11

Citation:

Persistent Link:
http://hdl.handle.net/11343/259540

File Description:
Published version

License:
CC BY-NC-ND